BeiGene | BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma

BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma

Beigene Study ID

BGB-A317-205

ClinicalTrials.gov ID

NCT03469557

China Drug Trials ID

CTR20170515

Study Overview

Sex: All

Age: 18 Years / 75 Years

No Study Documents

Study Overview

Sex: All

Age: 18 Years / 75 Years

No Study Documents